Yoda Pharmaceuticals Inc. (TPEX:7829)

Market Cap	5.98B +40.6%
Revenue (ttm)	n/a
Net Income	-364.07M
EPS	-4.08
Shares Out	99.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	143,348
Open	60.40
Previous Close	n/a
Day's Range	58.80 - 60.40
52-Week Range	36.20 - 67.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Yoda Pharmaceuticals

Yoda Pharmaceuticals Inc., an AI-driven company, focuses on development of drugs targeting central nervous system disorders. The company’s flagship drug, YA-101 is in Phase 2 clinical trial for the treatment of multiple system atrophy. It is also involved in the development pipeline includes drugs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions, such as schizophrenia, Alzheimer's disease, Parkinson‘s disease, Autism, ischemic stroke, and traumatic brain injury. Yoda Pharmaceuticals Inc. ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7829

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 30, 2026

Data Sources Report a data error